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EVALUATION OF __ N-( P-[  1251 ] IODOPHENYL)MALEIMIDE FOR LABELING MONOCLONAL 
ANTIBODIES ___ P. C. S r i v a s t a v a ,  F. F. Knapp, J r . ,  $1. F. A l l r e d  and tD.  J .  
Buchsbaum 
N u c l e a r  M e d i c i n e  Group,  Oak R i d g e  N a t i o n a l  L a b o r a t o r y ,  Oak R idge ,  TN, and 
t D e p a r t m e n t  o f  R a d i a t i o n  Therapy,  U n i v e r s i t y  o f  M i c h i g a n ,  Ann A r b o r ,  M I  
R a d i o l a b e l i n g  o f  monoc lona l  a n t i b o d i e s  (MoAb) w i t h  i o d i n e - 1 2 3  and 
i o d i n e - 1 3 1  i s  a t t r a c t i v e  f o r  d i a g n o s i s  and rad io immuno the rapy  o f  cance r .  
Some o f  t h e  number o f  r a d i o i o d i n a t i o n  p r o c e d u r e s  r e v i e w e d  r e c e n t l y  ( 1 )  
i n c l u d e  o x i d a t i v e  ( 2 )  and B o l t o n  H u n t e r  ( 3 )  t e c h n i q u e s  f o r  r a d i o l a b e l i n g  
a n t i b o d i e s .  
w i t h  t h e  o x i d i z i n g  agen t  and o t h e r  h a r s h  c o n d i t i o n s  a l l o w  t h e  l a b e l i n g  o f  
t y r o s i n e  p h e n o l i c  g roups  o r  amine f u n c t i o n a l  g roups  o f  t h e  p r o t e i n .  The 
m a j o r  d i s a d v a n t a g e s  of t h e s e  p r o c e d u r e s  i n c l u d e  t h e  p o s s i b i l i t y  of 
d e n a t u r a t i o n  r e s u l t i n g  i n  l o w  y i e l d s  and i n  v i v o  d e i o d i n a t i o n  r e s u l t i n g  i n  
dec reased  t i s s u e  h a l f - l i f e  o f  t h e  r a d i o l a b e l e d  MoAb. The r a t e  o f  
d e i o d i  n a t i o n  o f  r a d i o i o d i  n a t e d  p r o t e i n s  o f t e n  depends upon t h e  method o f  
i o d i n a t i o n  ( 4 ) .  The i n v e s t i g a t i o n s  f o r  l a b e l i n g  MoAbs t o  i n h i b i t  i n  v i v o  
d e i o d i n a t i o n  have been pu rsued  i n  o u r  l a b o r a t o r y .  
The N - s u b s t i t u t e d  m a l e i m i d e s  have n a t u r a l  a f f i n i t y  t o  r e a c t  w i t h  p r o t e i n -  
t h i o l s  f o r m i n g  a t h o e t h e r  l i n k a g e  u n d e r  m i l d  c o n d i t i o n s  ( 5 ) .  The 
o p p o r t u n i t y  f o r  s i t e - s p e c i f i c  p r o t e i n  r a d i o i o d i n a t i o n  l e d  us t o  d e s i g n  and 
s y n t h e s i z e  N-(p- [  1251]iodophenyl)maleimide (IPM, 2) i n  w h i c h  i o d i n e  i s  
s t a b i l i z e d  on t h e  p h e n y l  r i n g  a t t a c h e d  t o  t h e  n a l e i m i d e  m o i e t y  w i t h  
r e t e n t i o n  o f  t h i o l - b i n d i n g  r e a c t i v i t y  (6 ,7 ) .  I P M  has been p r e p a r e d  v i a  
N a C l Z 5 I 1  o r  [1251] IC1 i o d i n a t i o n  of t h e  mercu ry  a c e t a t e  k i t  (4) as shown i n  
Scheme I .  
F o r  a c o m p a r a t i v e  s t u d y ,  MoAb s p e c i f i c  t o  melanoma and c o l o n  tumors  was 
r a d i o l a b e l e d  by t h e  IC1 method (8 )  o r  by c o n j u g a t i o n  o f  I P M  by i n c u b a t i n g  
MoAb w i t h  IPM f o r  30 min a t  37OC. The e f f i c i e n c y  o f  i n c o r p o r a t i o n  o f  l Z 5 I  
i n  t h e  MoAb by IC1 o r  I P M  p r o c e d u r e s  was 19% (Sp. a c t .  0.14 mCi/mg) and 43% 
( s p .  a c t .  5 UCi/mg), r e s p e c t i v e l y .  I n  v i v o  t i s s u e  d i s t r i b u t i o n  f o l l o w i n g  
i .p. a d m i n i s t r a t i o n  o f  1 2 5 1 - l a b e l e d  MoAb ( I C 1 )  o r  l Z 5 I - l a b e l e d  MoAb ( IPM) 
p r e p a r a t i o n s  was conduc ted  i n  nude m i c e  ( 3  a n i m a l s / g r o u p )  i m p l a n t e d  w i t h  
c o l o n  carc inoma.  The tumor  u p t a k e  o f  r d d i o l a b e l e d  MoAb p r e p a r a t i o n s  a t  
v a r i o u s  t i m e s  a f t e r  i n j e c t i o n  i s  shown i n  F i g .  1. The IC1 p r e p a r a t i o n  
showed a maximum t u n o r  u p t a k e  o f  3.6% a t  12 h a f t e r  i n j e c t i o n ,  w h i c h  
d e c l i n e d  t o  2.7% a t  6 days. The I P M  p r e p a r a t i o n  showed a inaxiinum tumor  
u p t a k e  o f  1.5% a t  12 h a f t e r  i n j e c t i o n ,  w h i c h  d e c l i n e d  t o  0.5% a t  6 days. 
However, t h e  IC1 p r e p a r a t i o n  showed s u b s t a n t i a l l y  g r e a t e r  u p t a k e  i n  t h e  
t h y r o i d  w i t h  v a l u e s  o f  2.07% i .d . /g  a t  6 h a f t e r  i n j e c t i o n  r e a c h i n g  a 
maxiirlun o f  4.25% i . d . / g  a f t e r  6 days. I n  c o n t r a s t ,  t h e  IPM p r e p a r a t i o n  
showed a c o n s t a n t  l e v e l  of u p t a k e  i n  t h y r o i d  of 0.13- 0.17% i .d . /g  
( F i g .  3 ) .  
These t e c h n i q u e s  i n v o l v i n g  d i r e c t  exposure  o f  t h e  a n t i b o d y  
c 
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Fig .  1. Tumor up take  o f  r a d i o a c t i v i t y  f o l l o w i n g  i n t ravenous  a d m i n i s t r a t i o n  
o f  [1251]MoAb l a b e l e d  by IC1 o r  maleimide (IPM) techn iques  i n t o  
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F ig .  2. Thy ro id  up take  o f  r a d i o a c t i v i t y  f o l l o w i n g  in t ravenous 
a d m i n i s t r a t i o n  o f  [1251]MoAb l a b e l e d  by IC1 o r  maleimide ( I P M )  
techn iques  i n t o  nude mice bear ing  co lon  tumor. 
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The r e s u l t s  o f  t h e s e  p r e l i m i n a r y  s t u d i e s  d e m o n s t r a t e  t h a t  t h e  I P M  l a b e l e d  
MoAb showed m a r k e d l y  l e s s  u p t a k e  i n  t h y r o i d  i n d i c a t i n g  i n s i g n i f i c a n t  i n  
v i v o  d e i o d i n a t i o n  t h a n  c o n v e n t i o n a l l y  ( I C 1  ) l a b e l e d  MoAb, w h i l e  r e t a i n i n g  
t u m o r  u p t a k e  i n  v i v o .  
i o d i n a t i o n  c o n d i t i o n s  and t o  i m p r o v e  t h e  tumor  l o c a l i z a t i o n .  
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